Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2000

View Archived Issues

Corixa subscribes to Incyte's LifeSeq Gold database

Telomerase gene therapy may offer potential liver cirrhosis therapy

Myriad Genetics advances drug discovery programs during second quarter

Anti-tat gene therapy blocks HIV replication, may offer new treatment alternative

Altus receives funding for GI lipase enzyme therapy

YM-872 exerts neuroprotective effects in rat transient MCA occlusion model

Human Genome Sciences moves three drugs into clinical development in 1999

SkyePharma achieves positive phase II results for DepoMorphine; DepoCyt approved in Canada

GenVec licenses gene for treating blindness

New study contradicts earlier indications of efficacy for ERT in treating Alzheimer's disease

Elan/Endorex joint venture to develop iron-chelating products with Schein

Modified oligonucleotides with staggered PS/PO linkages designed at Isis

CAN-296 may inhibit fungal ATPase-mediated proton pumping

Synaptic discovers potent and selective human alpha1D-adrenoceptor antagonists

Study disproves earlier reports of serious treatment-related side effect of deferiprone

NPY Y1-selective compounds for diagnostic, therapeutic use available for licensing

Compounds activating PPAR isoforms described by Merck for lipid disorders, diabetes

Salk team identifies potential target for the elusive male contraceptive

Orally active antiplatelet agents in development at Lafon

Merck presents new nonpeptide GnRH antagonists

Immune Response's mbGM-CSF vaccine offers protection against melanoma

Pregabalin now claimed for renal colic-associated pain

Ono claims selective EP4 receptor ligands and their use

New treatment for COPD from Ono to enter clinical trials soon

AMPA antagonists improve neurological outcome in EAE

Nastech's NDA for intranasal scopolamine not accepted for filing

Remicade recommended for approval in E.U. for treatment of rheumatoid arthritis

FDA issues approvable letter for Pharmacia & Upjohn's Vestra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...